GLUCOVANCE
LOE ApproachingNDAORALTABLET
Approved
Jul 2000
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
2
Data completeness
3/8 — Basic
GLUCOVANCE by Bristol Myers Squibb is mechanism of action glucovance combines glyburide and metformin hydrochloride, 2 antihyperglycemic agents with complementary mechanisms of action, to improve glycemic control in patients with type 2 diabetes. First approved in 2000.
Drug data last refreshed 14h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
GLUCOVANCE is an oral fixed-dose combination tablet approved in 2000 that combines glyburide (a sulfonylurea) and metformin hydrochloride (a biguanide) to treat type 2 diabetes. Glyburide stimulates insulin release from pancreatic beta cells, while metformin decreases hepatic glucose production and improves insulin sensitivity. Together, these complementary mechanisms provide dual antihyperglycemic action.
LOE Approaching
As LOE approaches, the brand team is likely consolidating and focused on managed decline rather than growth initiatives.
Mechanism of Action
Mechanism of Action GLUCOVANCE combines glyburide and metformin hydrochloride, 2 antihyperglycemic agents with complementary mechanisms of action, to improve glycemic control in patients with type 2 diabetes. Glyburide appears to lower blood glucose acutely by stimulating the release of insulin…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (2)
A Research Study to Assess the Mechanism By Which Glucovance, Metformin, and Glyburide Work To Control Glucose Levels In Patients With Type 2 Diabetes
Started Feb 2002
Diabetes Mellitus, Non-Insulin-Dependent
A Research Study to Determine the Safety and Efficacy of Glucovance Compared to Metformin and Glyburide in Children and Adolescents With Type 2 Diabetes.
Started Dec 2001
Diabetes Mellitus, Non-Insulin-Dependent
Worked on GLUCOVANCE at Bristol Myers Squibb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.